We’re glad you’re enjoying
Poultry Health Today.


Access is free but you’ll need to
register to view more content.
Already registered? Sign In
X
OPEN IN APPOPEN IN APP

REPORTS

Collect articles and features into your own report to read later, print or share with others
CANCEL

Create a new report

Report title (required) Brief description (optional)
CREATE
CANCEL

Report: US poultry producers slash use of medically important antimicrobials while shifting focus to disease prevention

PHTweb CapeCodPress 120081796

US poultry producers drastically reduced their use of medically important antimicrobials over a 5-year period ending in 2017, according to a new report released by Randall Singer, DVM, PhD, Mindwalk Consulting Group, LLC.

This scientific report was supported by the US Food and Drug Administration (FDA) and the US Poultry & Egg Association (USPOULTRY).

“What made this special was that participation in the study was voluntary but nevertheless extensive,” Singer told Poultry Health Today.

For example, he noted, the 2017 data represented more than 7.5 billion chickens and 160 million turkeys — approximately 90% of annual US chicken production and 80% of annual US turkey production, based on a list of major US poultry companies compiled by WATT PoultryUSA.

Key changes among broiler chickens over the 5-year period show:

  • Broiler chickens receiving antimicrobials in the hatchery decreased from 93% to 17%.
  • Hatchery gentamicin use decreased approximately 74%.
  • Medically important in-feed antimicrobial use in broiler chickens decreased by as much as 95% (tetracycline).
  • Medically important water-soluble antimicrobial use in broiler chickens decreased by as much as 72% (sulfonamide).
  • There was a documented shift to the use of antimicrobials considered not medically important to humans by FDA (e.g., avilamycin and bacitracin).

Key changes among turkeys over the 5-year period show:

  • Turkeys receiving antimicrobials in the hatchery decreased from 96% to 41%.
  • Hatchery gentamicin use decreased approximately 42%.
  • Medically important in-feed antimicrobial use in turkeys decreased as much as 67% (tetracycline).
  • Medically important water-soluble antimicrobial use decreased substantially. For example:
    penicillin 42%, tetracycline 28%, lincomycin 46%, neomycin 49%, erythromycin 65%.

Given several key differences among broiler chickens and turkeys — namely differences in weight, life span, susceptibility to lifetime illness and the number of effective medical therapies available — the data from broiler chickens and turkeys should neither be combined nor compared, USPOULTRY said.

The report cited several reasons for the downturn in antimicrobial use:

  • Changes in FDA regulations, which were fully implemented in January 2017, effectively eliminated the use of medically important antimicrobials for production purposes and also required veterinary supervision for in-feed and water-soluble medically important antimicrobial uses in poultry production.
  • Poultry companies’ continued focus on hygiene practices, nutrition and vaccine use to prevent disease, thereby reducing the need to address disease with antimicrobials.
  • Improved recordkeeping of all antimicrobial administrations, which is a key component of antimicrobial stewardship.

Furthermore, the report noted, the broiler-chicken and turkey industries have increased the production of animals raised without antimicrobials.

Voluntary but extensive

The data were compiled under the research direction of Singer and looked at antimicrobial use in broiler chickens and turkeys from hatchery to day of harvest. The report was prepared through a systematic collection of on-farm antimicrobial-use data to capture the disease indications and routes of administration through which antimicrobials were given to the poultry.

“This research is the first step in determining how antimicrobials are used in the entire poultry-production system of the US, and to succeed, we need participation from the majority of companies. We couldn’t be more pleased with the response of the poultry industry,” said John Glisson, DVM, PhD, vice president of research, USPOULTRY.

Antimicrobials still needed

He cautioned there are still serious diseases — e.g., necrotic enteritis, gangrenous dermatitis and colibacillosis — for which the poultry industry has few effective interventions. When birds get sick from these diseases, they must receive antimicrobial therapy.

Glisson said that “driving good antimicrobial stewardship in poultry, as opposed to simple documentation of reduced use, is our end goal for the best outcomes for both the people and the poultry.”

Moving forward, Singer will continue the annual collection of data from the broiler-chicken and turkey industries and will begin collecting data from the US table-egg industry. The new data are expected to provide greater clarity about antimicrobial use in individual flocks.

“We expect even more detailed data on flock antimicrobial usage and recordkeeping in the years ahead, which thoroughly supports USPOULTRY efforts to ensure proper stewardship of medications,” Glisson said.

Click here to see the report.

Click here to see the infographic prepared by USPOULTRY.




Posted on August 8, 2019
  • Share
    Email
    Email
    Facebook
    Facebook
    Twitter
    Twitter
    LinkedIn
    LinkedIn
    Print
    Print

    Favorites

    Read Later

    My Reports